Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding.

Science Immunology
Lawrence P AndrewsKate M Vignali

Abstract

Mechanisms of resistance to cancer immunotherapy remain poorly understood. Lymphocyte activation gene-3 (LAG3) signaling is regulated by a disintegrin and metalloprotease domain-containing protein-10 (ADAM10)- and ADAM17-mediated cell surface shedding. Here, we show that mice expressing a metalloprotease-resistant, noncleavable LAG3 mutant (LAG3NC) are resistant to PD1 blockade and fail to mount an effective antitumor immune response. Expression of LAG3NC intrinsically perturbs CD4+ T conventional cells (Tconvs), limiting their capacity to provide CD8+ T cell help. Furthermore, the translational relevance for these observations is highlighted with an inverse correlation between high LAG3 and low ADAM10 expression on CD4+ Tconvs in the peripheral blood of patients with head and neck squamous cell carcinoma, which corresponded with poor prognosis. This correlation was also observed in a cohort of patients with skin cancers and was associated with increased disease progression after standard-of-care immunotherapy. These data suggest that subtle changes in LAG3 inhibitory receptor signaling can act as a resistance mechanism with a substantive effect on patient responsiveness to immunotherapy.

References

Nov 24, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Nianyu LiDario A A Vignali
Jan 25, 2007·The EMBO Journal·Nianyu LiDario A A Vignali
Feb 10, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Creg J WorkmanDario A A Vignali
Oct 2, 2009·Nature·Lorraine A O' ReillyAndreas Strasser
Oct 12, 2010·Science·Yuri P RubtsovAlexander Y Rudensky
May 29, 2012·Nucleic Acids Research·Di Wu, Gordon K Smyth
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Feb 5, 2013·Nature Immunology·Clifford S GuyDario A A Vignali
Jun 4, 2013·The New England Journal of Medicine·Omid HamidAntoni Ribas
Feb 18, 2014·Nature·Haipeng LiuDarrell J Irvine
Mar 5, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suzanne L TopalianF Stephen Hodi
May 6, 2015·The Journal of Clinical Investigation·Melissa C HansonDarrell J Irvine
May 29, 2015·European Journal of Immunology·Meghan E TurnisDario A A Vignali
Jun 30, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott GettingerMatthew D Hellmann
Aug 25, 2016·Oncotarget·Lei LiEnde Zhao
Oct 11, 2016·The New England Journal of Medicine·Robert L FerrisMaura L Gillison
Jan 17, 2017·Nature Communications·Grace X Y ZhengJason H Bielas
Mar 5, 2017·Immunological Reviews·Lawrence P AndrewsDario A A Vignali
May 13, 2017·Cell Reports·Kiyokazu KakugawaIchiro Taniuchi
Mar 1, 2018·Journal of Dental Research·J M Moskovitz, R L Ferris
Oct 27, 2018·European Journal of Immunology·Diana C YánezTessa Crompton
Feb 12, 2019·Nature Methods·George C LindermanYuval Kluger
Jun 11, 2019·Cell·Tim StuartRahul Satija
Oct 16, 2019·Nature Immunology·Lawrence P AndrewsDario A A Vignali
Dec 4, 2019·Immunology·Diana C YánezTessa Crompton
Jan 12, 2020·Immunity·Anthony R CilloDario A A Vignali

❮ Previous
Next ❯

Citations

Jan 26, 2021·Frontiers in Immunology·Colin G GraydonKeith R Fowke

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.